カテゴリー： LP Information, 世界, 医療/バイオ

世界の心血管疾患治療薬市場予測 2021年-2026年

【英語タイトル】Global Cardiovascular Disease Drugs Market Growth 2021-2026

LP Informationが出版した調査資料（LPI21MY9466）・商品コード：LPI21MY9466
・発行会社（調査会社）：LP Information
・発行日：2021年5月（※2024年版があります。お問い合わせください）
・ページ数：165
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥541,680見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥812,520見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,083,360見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・郵送（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
LPインフォメーション社の「心血管疾患治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他など、用途別には、虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他などにセグメント区分してまとめました。心血管疾患治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。
・心血管疾患治療薬の世界市場概要（サマリー）
・心血管疾患治療薬の企業別販売量・売上
・心血管疾患治療薬の企業別市場シェア
・心血管疾患治療薬の世界市場規模 2016年-2021年：種類別（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他）
・心血管疾患治療薬の世界市場規模 2016年-2021年：用途別（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他）
・心血管疾患治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど）
・心血管疾患治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）
・心血管疾患治療薬のヨーロッパ市場規模（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・心血管疾患治療薬の中東・アフリカ市場（エジプト、南アフリカ、トルコ、GCC諸国など）
・心血管疾患治療薬市場の成長要因・課題・動向
・心血管疾患治療薬の世界市場予測 2021年-2026年
・心血管疾患治療薬の南北アメリカ市場予測（アメリカ、カナダ、メキシコなど）
・心血管疾患治療薬のアジア市場予測（日本、中国、韓国、インド、東南アジアなど）
・心血管疾患治療薬のヨーロッパ市場予測（ドイツ、フランス、イギリス、イタリア、ロシアなど）
・心血管疾患治療薬の中東・アフリカ市場予測（エジプト、南アフリカ、トルコ、GCC諸国など）
・心血管疾患治療薬の世界市場予測：種類別（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロットレル、その他）
・心血管疾患治療薬の世界市場予測：用途別（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他）
・主要企業分析
【レポートの概要】

According to this latest study, the 2020 growth of Cardiovascular Disease Drugs will have significant change from previous year. By the most conservative estimates of global Cardiovascular Disease Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Cardiovascular Disease Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Disease Drugs market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Asischemic Heart Disease
Dyslipidemia
Stroke
Thrombosis
Atherosclerosis
Coronary Artery Diseases
Peripheral Artery Disease
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
AstraZeneca
Johnson＆Johnson
Pfizer
Sanofi
Merck
Daiichi Sankyo Company Limited
Novartis
Bayer
Takeda Pharmaceutical
Hoffmann-La Roche
United Therapeutics Corporation
Actelion Pharmaceuticals
Boehringer Ingelheim
Astellas Pharma

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Cardiovascular Disease Drugs Consumption 2016-2026
2.1.2 Cardiovascular Disease Drugs Consumption CAGR by Region
2.2 Cardiovascular Disease Drugs Segment by Type
2.2.1 Heparin
2.2.2 Coumadin
2.2.3 Sectral
2.2.4 Zebeta
2.2.5 Lopressor
2.2.6 Toprol XL
2.2.7 Norvasc
2.2.8 Lotrel
2.2.9 Others
2.3 Cardiovascular Disease Drugs Sales by Type
2.3.1 Global Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
2.3.2 Global Cardiovascular Disease Drugs Revenue and Market Share by Type (2016-2021)
2.3.3 Global Cardiovascular Disease Drugs Sale Price by Type (2016-2021)
2.4 Cardiovascular Disease Drugs Segment by Application
2.4.1 Asischemic Heart Disease
2.4.2 Dyslipidemia
2.4.3 Stroke
2.4.4 Thrombosis
2.4.5 Atherosclerosis
2.4.6 Coronary Artery Diseases
2.4.7 Peripheral Artery Disease
2.4.8 Others
2.5 Cardiovascular Disease Drugs Sales by Application
2.5.1 Global Cardiovascular Disease Drugs Sale Market Share by Application (2016-2021)
2.5.2 Global Cardiovascular Disease Drugs Revenue and Market Share by Application (2016-2021)
2.5.3 Global Cardiovascular Disease Drugs Sale Price by Application (2016-2021)

3 Global Cardiovascular Disease Drugs by Company
3.1 Global Cardiovascular Disease Drugs Sales Market Share by Company
3.1.1 Global Cardiovascular Disease Drugs Sales by Company (2019-2021)
3.1.2 Global Cardiovascular Disease Drugs Sales Market Share by Company (2019-2021)
3.2 Global Cardiovascular Disease Drugs Revenue Market Share by Company
3.2.1 Global Cardiovascular Disease Drugs Revenue by Company (2019-2021)
3.2.2 Global Cardiovascular Disease Drugs Revenue Market Share by Company (2019-2021)
3.3 Global Cardiovascular Disease Drugs Sale Price by Company
3.4 Global Manufacturers Cardiovascular Disease Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Cardiovascular Disease Drugs Product Location Distribution
3.4.2 Players Cardiovascular Disease Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Cardiovascular Disease Drugs by Region
4.1 Global Cardiovascular Disease Drugs by Region
4.1.1 Global Cardiovascular Disease Drugs Sales by Region
4.1.2 Global Cardiovascular Disease Drugs Revenue by Region
4.2 Americas Cardiovascular Disease Drugs Sales Growth
4.3 APAC Cardiovascular Disease Drugs Sales Growth
4.4 Europe Cardiovascular Disease Drugs Sales Growth
4.5 Middle East & Africa Cardiovascular Disease Drugs Sales Growth

5 Americas
5.1 Americas Cardiovascular Disease Drugs Sales by Country
5.1.1 Americas Cardiovascular Disease Drugs Sales by Country (2016-2021)
5.1.2 Americas Cardiovascular Disease Drugs Revenue by Country (2016-2021)
5.2 Americas Cardiovascular Disease Drugs Sales by Type
5.3 Americas Cardiovascular Disease Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Cardiovascular Disease Drugs Sales by Region
6.1.1 APAC Cardiovascular Disease Drugs Sales by Region (2016-2021)
6.1.2 APAC Cardiovascular Disease Drugs Revenue by Region (2016-2021)
6.2 APAC Cardiovascular Disease Drugs Sales by Type
6.3 APAC Cardiovascular Disease Drugs Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Cardiovascular Disease Drugs by Country
7.1.1 Europe Cardiovascular Disease Drugs Sales by Country (2016-2021)
7.1.2 Europe Cardiovascular Disease Drugs Revenue by Country (2016-2021)
7.2 Europe Cardiovascular Disease Drugs Sales by Type
7.3 Europe Cardiovascular Disease Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Cardiovascular Disease Drugs by Country
8.1.1 Middle East & Africa Cardiovascular Disease Drugs Sales by Country (2016-2021)
8.1.2 Middle East & Africa Cardiovascular Disease Drugs Revenue by Country (2016-2021)
8.2 Middle East & Africa Cardiovascular Disease Drugs Sales by Type
8.3 Middle East & Africa Cardiovascular Disease Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Cardiovascular Disease Drugs Distributors
10.3 Cardiovascular Disease Drugs Customer

11 Global Cardiovascular Disease Drugs Market Forecast
11.1 Global Cardiovascular Disease Drugs Forecast by Region
11.1.1 Global Cardiovascular Disease Drugs Forecast by Regions (2021-2026)
11.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Cardiovascular Disease Drugs Forecast by Type
11.7 Global Cardiovascular Disease Drugs Forecast by Application

12 Key Players Analysis
12.1 AstraZeneca
12.1.1 AstraZeneca AstraZeneca Company Information
12.1.2 AstraZeneca Cardiovascular Disease Drugs Product Offered
12.1.3 AstraZeneca Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 AstraZeneca Main Business Overview
12.1.5 AstraZeneca Latest Developments
12.2 Johnson＆Johnson
12.2.1 Johnson＆Johnson Company Information
12.2.2 Johnson＆Johnson Cardiovascular Disease Drugs Product Offered
12.2.3 Johnson＆Johnson Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Johnson＆Johnson Main Business Overview
12.2.5 Johnson＆Johnson Latest Developments
12.3 Pfizer
12.3.1 Pfizer Company Information
12.3.2 Pfizer Cardiovascular Disease Drugs Product Offered
12.3.3 Pfizer Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 Pfizer Main Business Overview
12.3.5 Pfizer Latest Developments
12.4 Sanofi
12.4.1 Sanofi Company Information
12.4.2 Sanofi Cardiovascular Disease Drugs Product Offered
12.4.3 Sanofi Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Sanofi Main Business Overview
12.4.5 Sanofi Latest Developments
12.5 Merck
12.5.1 Merck Company Information
12.5.2 Merck Cardiovascular Disease Drugs Product Offered
12.5.3 Merck Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Merck Main Business Overview
12.5.5 Merck Latest Developments
12.6 Daiichi Sankyo Company Limited
12.6.1 Daiichi Sankyo Company Limited Company Information
12.6.2 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Offered
12.6.3 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Daiichi Sankyo Company Limited Main Business Overview
12.6.5 Daiichi Sankyo Company Limited Latest Developments
12.7 Novartis
12.7.1 Novartis Company Information
12.7.2 Novartis Cardiovascular Disease Drugs Product Offered
12.7.3 Novartis Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Novartis Main Business Overview
12.7.5 Novartis Latest Developments
12.8 Bayer
12.8.1 Bayer Company Information
12.8.2 Bayer Cardiovascular Disease Drugs Product Offered
12.8.3 Bayer Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Bayer Main Business Overview
12.8.5 Bayer Latest Developments
12.9 Takeda Pharmaceutical
12.9.1 Takeda Pharmaceutical Company Information
12.9.2 Takeda Pharmaceutical Cardiovascular Disease Drugs Product Offered
12.9.3 Takeda Pharmaceutical Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Takeda Pharmaceutical Main Business Overview
12.9.5 Takeda Pharmaceutical Latest Developments
12.10 Hoffmann-La Roche
12.10.1 Hoffmann-La Roche Company Information
12.10.2 Hoffmann-La Roche Cardiovascular Disease Drugs Product Offered
12.10.3 Hoffmann-La Roche Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.10.4 Hoffmann-La Roche Main Business Overview
12.10.5 Hoffmann-La Roche Latest Developments
12.11 United Therapeutics Corporation
12.11.1 United Therapeutics Corporation Company Information
12.11.2 United Therapeutics Corporation Cardiovascular Disease Drugs Product Offered
12.11.3 United Therapeutics Corporation Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.11.4 United Therapeutics Corporation Main Business Overview
12.11.5 United Therapeutics Corporation Latest Developments
12.12 Actelion Pharmaceuticals
12.12.1 Actelion Pharmaceuticals Company Information
12.12.2 Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Offered
12.12.3 Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.12.4 Actelion Pharmaceuticals Main Business Overview
12.12.5 Actelion Pharmaceuticals Latest Developments
12.13 Boehringer Ingelheim
12.13.1 Boehringer Ingelheim Company Information
12.13.2 Boehringer Ingelheim Cardiovascular Disease Drugs Product Offered
12.13.3 Boehringer Ingelheim Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.13.4 Boehringer Ingelheim Main Business Overview
12.13.5 Boehringer Ingelheim Latest Developments
12.14 Astellas Pharma
12.14.1 Astellas Pharma Company Information
12.14.2 Astellas Pharma Cardiovascular Disease Drugs Product Offered
12.14.3 Astellas Pharma Cardiovascular Disease Drugs Sales, Revenue, Price and Gross Margin (2019-2021)
12.14.4 Astellas Pharma Main Business Overview
12.14.5 Astellas Pharma Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Cardiovascular Disease Drugs Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Heparin
Table 3. Major Players of Coumadin
Table 4. Major Players of Sectral
Table 5. Major Players of Zebeta
Table 6. Major Players of Lopressor
Table 7. Major Players of Toprol XL
Table 8. Major Players of Norvasc
Table 9. Major Players of Lotrel
Table 10. Major Players of Others
Table 11. Global Cardiovascular Disease Drugs Sales by Type (2016-2021) & (K Units)
Table 12. Global Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
Table 13. Global Cardiovascular Disease Drugs Revenue by Type (2016-2021) & ($ million)
Table 14. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2016-2021)
Table 15. Global Cardiovascular Disease Drugs Sale Price by Type (2016-2021)
Table 16. Global Cardiovascular Disease Drugs Sales by Application (2016-2021) & (K Units)
Table 17. Global Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Table 18. Global Cardiovascular Disease Drugs Value by Application (2016-2021)
Table 19. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2016-2021)
Table 20. Global Cardiovascular Disease Drugs Sale Price by Application (2016-2021)
Table 21. Global Cardiovascular Disease Drugs Sales by Company (2019-2021) & (K Units)
Table 22. Global Cardiovascular Disease Drugs Sales Market Share by Company (2019-2021)
Table 23. Global Cardiovascular Disease Drugs Revenue by Company (2019-2021) ($ Millions)
Table 24. Global Cardiovascular Disease Drugs Revenue Market Share by Company (2019-2021)
Table 25. Global Cardiovascular Disease Drugs Sale Price by Company (2019-2021)
Table 26. Key Manufacturers Cardiovascular Disease Drugs Producing Area Distribution and Sales Area
Table 27. Players Cardiovascular Disease Drugs Products Offered
Table 28. Cardiovascular Disease Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 29. New Products and Potential Entrants
Table 30. Mergers & Acquisitions, Expansion
Table 31. Global Cardiovascular Disease Drugs Sales by Region (2016-2021) (K Units)
Table 32. Global Cardiovascular Disease Drugs Sales Market Share by Region (2016-2021)
Table 33. Global Cardiovascular Disease Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 34. Global Cardiovascular Disease Drugs Revenue Market Share by Region (2016-2021)
Table 35. Americas Cardiovascular Disease Drugs Sales by Country (2016-2021) & (K Units)
Table 36. Americas Cardiovascular Disease Drugs Sales Market Share by Country (2016-2021)
Table 37. Americas Cardiovascular Disease Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 38. Americas Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2021)
Table 39. Americas Cardiovascular Disease Drugs Sales by Type (2016-2021) & (K Units)
Table 40. Americas Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
Table 41. Americas Cardiovascular Disease Drugs Sales by Application (2016-2021) & (K Units)
Table 42. Americas Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Table 43. APAC Cardiovascular Disease Drugs Sales by Region (2016-2021) & (K Units)
Table 44. APAC Cardiovascular Disease Drugs Sales Market Share by Region (2016-2021)
Table 45. APAC Cardiovascular Disease Drugs Revenue by Region (2016-2021) & ($ Millions)
Table 46. APAC Cardiovascular Disease Drugs Revenue Market Share by Region (2016-2021)
Table 47. APAC Cardiovascular Disease Drugs Sales by Type (2016-2021) & (K Units)
Table 48. APAC Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
Table 49. APAC Cardiovascular Disease Drugs Sales by Application (2016-2021) & (K Units)
Table 50. APAC Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Table 51. Europe Cardiovascular Disease Drugs Sales by Country (2016-2021) & (K Units)
Table 52. Europe Cardiovascular Disease Drugs Sales Market Share by Country (2016-2021)
Table 53. Europe Cardiovascular Disease Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 54. Europe Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2021)
Table 55. Europe Cardiovascular Disease Drugs Sales by Type (2016-2021) & (K Units)
Table 56. Europe Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
Table 57. Europe Cardiovascular Disease Drugs Sales by Application (2016-2021) & (K Units)
Table 58. Europe Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Table 59. Middle East & Africa Cardiovascular Disease Drugs Sales by Country (2016-2021) & (K Units)
Table 60. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Country (2016-2021)
Table 61. Middle East & Africa Cardiovascular Disease Drugs Revenue by Country (2016-2021) & ($ Millions)
Table 62. Middle East & Africa Cardiovascular Disease Drugs Revenue Market Share by Country (2016-2021)
Table 63. Middle East & Africa Cardiovascular Disease Drugs Sales by Type (2016-2021) & (K Units)
Table 64. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Type (2016-2021)
Table 65. Middle East & Africa Cardiovascular Disease Drugs Sales by Application (2016-2021) & (K Units)
Table 66. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Table 67. Global Cardiovascular Disease Drugs Sales Forecast by Type (2021-2026) & (K Units)
Table 68. Global Cardiovascular Disease Drugs Sales Market Share Forecast by Type (2021-2026)
Table 69. Global Cardiovascular Disease Drugs Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 70. Global Cardiovascular Disease Drugs Revenue Market Share Forecast by Type (2021-2026)
Table 71. Global Cardiovascular Disease Drugs Sales Forecast by Application (2021-2026) & (K Units)
Table 72. Global Cardiovascular Disease Drugs Sales Market Share Forecast by Application (2021-2026)
Table 73. Global Cardiovascular Disease Drugs Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 74. Global Cardiovascular Disease Drugs Revenue Market Share Forecast by Application (2021-2026)
Table 75. AstraZeneca Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 76. AstraZeneca Cardiovascular Disease Drugs Product Offered
Table 77. AstraZeneca Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 78. AstraZeneca Main Business
Table 79. AstraZeneca Latest Developments
Table 80. Johnson＆Johnson Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 81. Johnson＆Johnson Cardiovascular Disease Drugs Product Offered
Table 82. Johnson＆Johnson Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 83. Johnson＆Johnson Main Business
Table 84. Johnson＆Johnson Latest Developments
Table 85. Pfizer Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 86. Pfizer Cardiovascular Disease Drugs Product Offered
Table 87. Pfizer Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 88. Pfizer Main Business
Table 89. Pfizer Latest Developments
Table 90. Sanofi Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 91. Sanofi Cardiovascular Disease Drugs Product Offered
Table 92. Sanofi Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 93. Sanofi Main Business
Table 94. Sanofi Latest Developments
Table 95. Merck Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 96. Merck Cardiovascular Disease Drugs Product Offered
Table 97. Merck Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 98. Merck Main Business
Table 99. Merck Latest Developments
Table 100. Daiichi Sankyo Company Limited Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 101. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Product Offered
Table 102. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 103. Daiichi Sankyo Company Limited Main Business
Table 104. Daiichi Sankyo Company Limited Latest Developments
Table 105. Novartis Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 106. Novartis Cardiovascular Disease Drugs Product Offered
Table 107. Novartis Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 108. Novartis Main Business
Table 109. Novartis Latest Developments
Table 110. Bayer Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 111. Bayer Cardiovascular Disease Drugs Product Offered
Table 112. Bayer Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 113. Bayer Main Business
Table 114. Bayer Latest Developments
Table 115. Takeda Pharmaceutical Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 116. Takeda Pharmaceutical Cardiovascular Disease Drugs Product Offered
Table 117. Takeda Pharmaceutical Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 118. Takeda Pharmaceutical Main Business
Table 119. Takeda Pharmaceutical Latest Developments
Table 120. Hoffmann-La Roche Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 121. Hoffmann-La Roche Cardiovascular Disease Drugs Product Offered
Table 122. Hoffmann-La Roche Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 123. Hoffmann-La Roche Main Business
Table 124. Hoffmann-La Roche Latest Developments
Table 125. United Therapeutics Corporation Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 126. United Therapeutics Corporation Cardiovascular Disease Drugs Product Offered
Table 127. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 128. United Therapeutics Corporation Main Business
Table 129. United Therapeutics Corporation Latest Developments
Table 130. Actelion Pharmaceuticals Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 131. Actelion Pharmaceuticals Cardiovascular Disease Drugs Product Offered
Table 132. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 133. Actelion Pharmaceuticals Main Business
Table 134. Actelion Pharmaceuticals Latest Developments
Table 135. Boehringer Ingelheim Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 136. Boehringer Ingelheim Cardiovascular Disease Drugs Product Offered
Table 137. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 138. Boehringer Ingelheim Main Business
Table 139. Boehringer Ingelheim Latest Developments
Table 140. Astellas Pharma Basic Information, Cardiovascular Disease Drugs Manufacturing Base, Sales Area and Its Competitors
Table 141. Astellas Pharma Cardiovascular Disease Drugs Product Offered
Table 142. Astellas Pharma Cardiovascular Disease Drugs Sales (K Units), Revenue ($ Million), Price (USD/Units) and Gross Margin (2019-2021E)
Table 143. Astellas Pharma Main Business
Table 144. Astellas Pharma Latest Developments
List of Figures
Figure 1. Picture of Cardiovascular Disease Drugs
Figure 2. Cardiovascular Disease Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Cardiovascular Disease Drugs Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Cardiovascular Disease Drugs Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Cardiovascular Disease Drugs Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Heparin
Figure 10. Product Picture of Coumadin
Figure 11. Product Picture of Sectral
Figure 12. Product Picture of Zebeta
Figure 13. Product Picture of Lopressor
Figure 14. Product Picture of Toprol XL
Figure 15. Product Picture of Norvasc
Figure 16. Product Picture of Lotrel
Figure 17. Product Picture of Others
Figure 18. Global Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 19. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2016-2021)
Figure 20. Cardiovascular Disease Drugs Consumed in Asischemic Heart Disease
Figure 21. Global Cardiovascular Disease Drugs Market: Asischemic Heart Disease (2016-2021) & (K Units)
Figure 22. Cardiovascular Disease Drugs Consumed in Dyslipidemia
Figure 23. Global Cardiovascular Disease Drugs Market: Dyslipidemia (2016-2021) & (K Units)
Figure 24. Cardiovascular Disease Drugs Consumed in Stroke
Figure 25. Global Cardiovascular Disease Drugs Market: Stroke (2016-2021) & (K Units)
Figure 26. Cardiovascular Disease Drugs Consumed in Thrombosis
Figure 27. Global Cardiovascular Disease Drugs Market: Thrombosis (2016-2021) & (K Units)
Figure 28. Cardiovascular Disease Drugs Consumed in Atherosclerosis
Figure 29. Global Cardiovascular Disease Drugs Market: Atherosclerosis (2016-2021) & (K Units)
Figure 30. Cardiovascular Disease Drugs Consumed in Coronary Artery Diseases
Figure 31. Global Cardiovascular Disease Drugs Market: Coronary Artery Diseases (2016-2021) & (K Units)
Figure 32. Cardiovascular Disease Drugs Consumed in Peripheral Artery Disease
Figure 33. Global Cardiovascular Disease Drugs Market: Peripheral Artery Disease (2016-2021) & (K Units)
Figure 34. Cardiovascular Disease Drugs Consumed in Others
Figure 35. Global Cardiovascular Disease Drugs Market: Others (2016-2021) & (K Units)
Figure 36. Global Cardiovascular Disease Drugs Sales Market Share by Application (2016-2021)
Figure 37. Global Cardiovascular Disease Drugs Revenue Market Share by Application in 2020
Figure 38. Global Cardiovascular Disease Drugs Revenue Market by Company in 2020 ($ Million)
Figure 39. Global Cardiovascular Disease Drugs Revenue Market Share by Company in 2020
Figure 40. Global Cardiovascular Disease Drugs Sales Market Share by Regions (2016-2021)
Figure 41. Global Cardiovascular Disease Drugs Revenue Market Share by Region in 2020
Figure 42. Americas Cardiovascular Disease Drugs Sales 2016-2021 (K Units)
Figure 43. Americas Cardiovascular Disease Drugs Revenue 2016-2021 ($ Millions)
Figure 44. APAC Cardiovascular Disease Drugs Sales 2016-2021 (K Units)
Figure 45. APAC Cardiovascular Disease Drugs Revenue 2016-2021 ($ Millions)
Figure 46. Europe Cardiovascular Disease Drugs Sales 2016-2021 (K Units)
Figure 47. Europe Cardiovascular Disease Drugs Revenue 2016-2021 ($ Millions)
Figure 48. Middle East & Africa Cardiovascular Disease Drugs Sales 2016-2021 (K Units)
Figure 49. Middle East & Africa Cardiovascular Disease Drugs Revenue 2016-2021 ($ Millions)
Figure 50. Americas Cardiovascular Disease Drugs Sales Market Share by Country in 2020
Figure 51. Americas Cardiovascular Disease Drugs Revenue Market Share by Country in 2020
Figure 52. Americas Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 53. Americas Cardiovascular Disease Drugs Sales Market Share by Application in 2020
Figure 54. United States Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 55. Canada Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 56. Mexico Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 57. Brazil Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 58. APAC Cardiovascular Disease Drugs Sales Market Share by Region in 2020
Figure 59. APAC Cardiovascular Disease Drugs Revenue Market Share by Regions in 2020
Figure 60. APAC Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 61. APAC Cardiovascular Disease Drugs Sales Market Share by Application in 2020
Figure 62. China Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 63. Japan Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 64. Korea Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 65. Southeast Asia Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 66. India Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 67. Australia Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 68. Europe Cardiovascular Disease Drugs Sales Market Share by Country in 2020
Figure 69. Europe Cardiovascular Disease Drugs Revenue Market Share by Country in 2020
Figure 70. Europe Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 71. Europe Cardiovascular Disease Drugs Sales Market Share by Application in 2020
Figure 72. Germany Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 73. France Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 74. UK Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 75. Italy Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 76. Russia Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 77. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Country in 2020
Figure 78. Middle East & Africa Cardiovascular Disease Drugs Revenue Market Share by Country in 2020
Figure 79. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Type in 2020
Figure 80. Middle East & Africa Cardiovascular Disease Drugs Sales Market Share by Application in 2020
Figure 81. Egypt Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 82. South Africa Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 83. Israel Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 84. Turkey Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 85. GCC Country Cardiovascular Disease Drugs Revenue Growth 2016-2021 ($ Millions)
Figure 86. Channels of Distribution
Figure 87. Distributors Profiles


★調査レポート[世界の心血管疾患治療薬市場予測 2021年-2026年] (コード：LPI21MY9466)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の心血管疾患治療薬市場予測 2021年-2026年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のゴーシェ病治療薬市場予測 2021年-2026年
    LPI21MY9538 / LP Information / 2021年5月 / LPインフォメーション社の「ゴーシェ病治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、酵素、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症治療薬など、用途別には、I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病などにセグメント区分してまとめました。ゴーシェ病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ゴーシェ病治療薬の世界市場概要（サマリー） ・ゴーシェ病治療薬の企業別販売量・売上 ・ゴーシェ病治療薬の企業別市場シェア ・ゴーシェ病治療薬の世界市場規模 2016年-2021年：種類別（酵素、グルコシルセラミドシンターゼ阻害剤、骨粗鬆症治療薬） ・ゴーシェ病治療薬の世界市場規模 2016年-2021年：用途別（I型ゴーシェ病、II型ゴーシェ病、III型ゴーシェ病） ・ゴーシェ病治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ゴーシェ病治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Gaucher Disease Drugs will have significant change from previous year. By the most conservative estimates of global Gaucher Disease Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1292.3 million in 2019. Over the next five years the Gaucher Disease Drugs market will register a 0.6% CAGR in terms of revenue, the global market size will reach US$ 1326.1 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Gaucher Disease Drugs market by product type,...
  • 世界の心血管・脳血管API市場予測 2021年-2026年
    LPI21MY0941 / LP Information / 2021年5月 / LPインフォメーション社の「心血管・脳血管APIの世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、サルタン心血管・脳血管API、スタチン心血管・脳血管API、プリ心血管・脳血管APIなど、用途別には、経口薬、注射薬などにセグメント区分してまとめました。心血管・脳血管APIのグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管・脳血管APIの世界市場概要（サマリー） ・心血管・脳血管APIの企業別販売量・売上 ・心血管・脳血管APIの企業別市場シェア ・心血管・脳血管APIの世界市場規模 2016年-2021年：種類別（サルタン心血管・脳血管API、スタチン心血管・脳血管API、プリ心血管・脳血管API） ・心血管・脳血管APIの世界市場規模 2016年-2021年：用途別（経口薬、注射薬） ・心血管・脳血管APIの南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管・脳血管APIのアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Cardiovascular and Cerebrovascular API will have significant change from previous year. By the most conservative estimates of global Cardiovascular and Cerebrovascular API market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ 2941.1 million in 2020. Over the next five years the Cardiovascular and Cerebrovascular API market will register a 2.8% CAGR in terms of revenue, the global market size will reach US$ 3282 million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular and Cerebrovascular API...
  • 世界の自己投与薬市場予測 2021年-2026年
    LPI21MY9572 / LP Information / 2021年5月 / LPインフォメーション社の「自己投与薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、注射薬、吸入薬、経皮吸収薬など、用途別には、心血管疾患、糖尿病、骨粗鬆症、疼痛管理、ホルモン補充療法、その他などにセグメント区分してまとめました。自己投与薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・自己投与薬の世界市場概要（サマリー） ・自己投与薬の企業別販売量・売上 ・自己投与薬の企業別市場シェア ・自己投与薬の世界市場規模 2016年-2021年：種類別（注射薬、吸入薬、経皮吸収薬） ・自己投与薬の世界市場規模 2016年-2021年：用途別（心血管疾患、糖尿病、骨粗鬆症、疼痛管理、ホルモン補充療法、その他） ・自己投与薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・自己投与薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Self-administered Drugs will have significant change from previous year. By the most conservative estimates of global Self-administered Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Self-administered Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Self-administered Drugs market by product type, application, key manufacturers and...
  • 世界のオータコイド・関連薬市場予測 2021年-2026年
    LPI21MY9433 / LP Information / 2021年5月 / LPインフォメーション社の「オータコイド・関連薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、ポリペプチド、脱炭酸アミノ酸、エイコサノイドなど、用途別には、アレルギー、炎症、胃酸分泌、神経内分泌調節、慢性疼痛、心血管疾患、胃腸疾患などにセグメント区分してまとめました。オータコイド・関連薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・オータコイド・関連薬の世界市場概要（サマリー） ・オータコイド・関連薬の企業別販売量・売上 ・オータコイド・関連薬の企業別市場シェア ・オータコイド・関連薬の世界市場規模 2016年-2021年：種類別（ポリペプチド、脱炭酸アミノ酸、エイコサノイド） ・オータコイド・関連薬の世界市場規模 2016年-2021年：用途別（アレルギー、炎症、胃酸分泌、神経内分泌調節、慢性疼痛、心血管疾患、胃腸疾患） ・オータコイド・関連薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・オータコイド・関連薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Autacoids and Related Drugs will have significant change from previous year. By the most conservative estimates of global Autacoids and Related Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Autacoids and Related Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Autacoids and Related Drugs...
  • 世界の心血管補綴装置市場予測 2021年-2026年
    LPI21MY8807 / LP Information / 2021年5月 / LPインフォメーション社の「心血管補綴装置の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、心臓補綴装置、血管補綴装置など、用途別には、手術、研究などにセグメント区分してまとめました。心血管補綴装置のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管補綴装置の世界市場概要（サマリー） ・心血管補綴装置の企業別販売量・売上 ・心血管補綴装置の企業別市場シェア ・心血管補綴装置の世界市場規模 2016年-2021年：種類別（心臓補綴装置、血管補綴装置） ・心血管補綴装置の世界市場規模 2016年-2021年：用途別（手術、研究） ・心血管補綴装置の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管補綴装置のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cardiovascular Prosthetic Devices will have significant change from previous year. By the most conservative estimates of global Cardiovascular Prosthetic Devices market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 34840 million in 2019. Over the next five years the Cardiovascular Prosthetic Devices market will register a 4.0% CAGR in terms of revenue, the global market size will reach US$ 40760 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Prosthetic Devices market by product type,...
  • 世界の心血管手術用装置市場予測 2021年-2026年
    LPI21MY8808 / LP Information / 2021年5月 / LPインフォメーション社の「心血管手術用装置の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、灌流用使い捨て品、心肺バイパス装置、鼓動心臓手術治療、補助人工心臓、心臓アブレーション装置、その他など、用途別には、介入心臓手術、心臓リズム管理、従来型心臓手術、その他などにセグメント区分してまとめました。心血管手術用装置のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管手術用装置の世界市場概要（サマリー） ・心血管手術用装置の企業別販売量・売上 ・心血管手術用装置の企業別市場シェア ・心血管手術用装置の世界市場規模 2016年-2021年：種類別（灌流用使い捨て品、心肺バイパス装置、鼓動心臓手術治療、補助人工心臓、心臓アブレーション装置、その他） ・心血管手術用装置の世界市場規模 2016年-2021年：用途別（介入心臓手術、心臓リズム管理、従来型心臓手術、その他） ・心血管手術用装置の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管手術用装置のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cardiovascular Surgical Devices will have significant change from previous year. By the most conservative estimates of global Cardiovascular Surgical Devices market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 42150 million in 2019. Over the next five years the Cardiovascular Surgical Devices market will register a 5.5% CAGR in terms of revenue, the global market size will reach US$ 52270 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Surgical Devices market by product type,...
  • 世界のハンセン病治療薬市場予測 2021年-2026年
    LPI21MY9549 / LP Information / 2021年5月 / LPインフォメーション社の「ハンセン病治療薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、クロファジミン、サリドマイド、その他など、用途別には、病院、クリニック、その他などにセグメント区分してまとめました。ハンセン病治療薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・ハンセン病治療薬の世界市場概要（サマリー） ・ハンセン病治療薬の企業別販売量・売上 ・ハンセン病治療薬の企業別市場シェア ・ハンセン病治療薬の世界市場規模 2016年-2021年：種類別（クロファジミン、サリドマイド、その他） ・ハンセン病治療薬の世界市場規模 2016年-2021年：用途別（病院、クリニック、その他） ・ハンセン病治療薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・ハンセン病治療薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2021 growth of Hansen's Disease Therapeutics will have significant change from previous year. By the most conservative estimates of global Hansen's Disease Therapeutics market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Hansen's Disease Therapeutics market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026. This report presents a comprehensive overview, market shares, and growth opportunities of Hansen's Disease Therapeutics market by product type,...
  • 世界の心血管超音波市場予測 2021年-2026年
    LPI21MY8810 / LP Information / 2021年5月 / LPインフォメーション社の「心血管超音波の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、経胸壁心エコー図、経食道心エコー図、ストレス心エコー図、その他心エコー図など、用途別には、病院、循環器センター、外来、在宅医療、外来センター、その他などにセグメント区分してまとめました。心血管超音波のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管超音波の世界市場概要（サマリー） ・心血管超音波の企業別販売量・売上 ・心血管超音波の企業別市場シェア ・心血管超音波の世界市場規模 2016年-2021年：種類別（経胸壁心エコー図、経食道心エコー図、ストレス心エコー図、その他心エコー図） ・心血管超音波の世界市場規模 2016年-2021年：用途別（病院、循環器センター、外来、在宅医療、外来センター、その他） ・心血管超音波の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管超音波のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cardiovascular Ultrasound will have significant change from previous year. By the most conservative estimates of global Cardiovascular Ultrasound market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1099.9 million in 2019. Over the next five years the Cardiovascular Ultrasound market will register a 5.3% CAGR in terms of revenue, the global market size will reach US$ 1352 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular Ultrasound market by product type, application, key manufacturers and...
  • 世界の心血管手術用装置・技術市場予測 2021年-2026年
    LPI21MY8809 / LP Information / 2021年5月 / LPインフォメーション社の「心血管手術用装置・技術の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、鼓動用心臓手術システム、灌流使い捨て品、CPB機器、心臓アブレーション装置など、用途別には、医療機器製造会社、研究所、製薬会社、学術・医療機関などにセグメント区分してまとめました。心血管手術用装置・技術のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・心血管手術用装置・技術の世界市場概要（サマリー） ・心血管手術用装置・技術の企業別販売量・売上 ・心血管手術用装置・技術の企業別市場シェア ・心血管手術用装置・技術の世界市場規模 2016年-2021年：種類別（鼓動用心臓手術システム、灌流使い捨て品、CPB機器、心臓アブレーション装置） ・心血管手術用装置・技術の世界市場規模 2016年-2021年：用途別（医療機器製造会社、研究所、製薬会社、学術・医療機関） ・心血管手術用装置・技術の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・心血管手術用装置・技術のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Cardiovascular Surgical Devices and Technologies will have significant change from previous year. By the most conservative estimates of global Cardiovascular Surgical Devices and Technologies market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 1369 million in 2019. Over the next five years the Cardiovascular Surgical Devices and Technologies market will register a 3.9% CAGR in terms of revenue, the global market size will reach US$ 1594.3 million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Cardiovascular...
  • 世界の点眼薬市場予測 2021年-2026年
    LPI21MY9609 / LP Information / 2021年5月 / LPインフォメーション社の「点眼薬の世界市場」調査資料は、南北アメリカ、アジア、ヨーロッパ、中東・アフリカ市場を対象にしており、種類別には、網膜障害治療薬、アレルギー治療薬、炎症治療薬、感染治療薬、緑内障治療薬、ドライアイ治療薬など、用途別には、緑内障、ドライアイ症候群、網膜疾患、その他などにセグメント区分してまとめました。点眼薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が掲載されています。 ・点眼薬の世界市場概要（サマリー） ・点眼薬の企業別販売量・売上 ・点眼薬の企業別市場シェア ・点眼薬の世界市場規模 2016年-2021年：種類別（網膜障害治療薬、アレルギー治療薬、炎症治療薬、感染治療薬、緑内障治療薬、ドライアイ治療薬） ・点眼薬の世界市場規模 2016年-2021年：用途別（緑内障、ドライアイ症候群、網膜疾患、その他） ・点眼薬の南北アメリカ市場規模（アメリカ、カナダ、メキシコなど） ・点眼薬のアジア市場規模（日本、中国、韓国、インド、東南アジアなど）...According to this latest study, the 2020 growth of Ophthalmol Drugs will have significant change from previous year. By the most conservative estimates of global Ophthalmol Drugs market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Ophthalmol Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025. This report presents a comprehensive overview, market shares, and growth opportunities of Ophthalmol Drugs market by product type, application, key manufacturers and...

    • ◆H&Iグローバルリサーチのお客様（例）◆